05th week of 2010 patent applcation highlights part 57 |
Patent application number | Title | Published |
20100029698 | Pesticidal Mixtures - The present invention relates to mixtures comprising, as active components, 1) an insecticidal compound I selected from fipronil and ethiprole; and 2) a fungicidal compound IIA selected from azoles, strobilurins, carboxamides, heterocylic compounds, carbamates, and other active compounds, and optionally 3) one or two fungicidal compounds IIB selected from List B which is defined as List A plus triticonazole, orysastrobin, in synergistically effective amounts, all as further defined in the description. | 2010-02-04 |
20100029699 | MATRIX METALLOPROTEINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 2010-02-04 |
20100029700 | 1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS - Novel acetophenone compounds of formula (I), compositions containing (I), processes for the preparation of (I), and use of (I) as inhibitors of the glycine transporter, are provided. | 2010-02-04 |
20100029701 | MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention is directed to compounds of formula (I) | 2010-02-04 |
20100029702 | Method For Identification of Compound Having Anti-Anxiety Effect - There are provided a method for identifying a compound having an anti-anxiety effect, an inhibitor of a function of a protein having a function as a G-protein coupled receptor, characterized by finding the protein and a gene encoding the protein and using at least one of a DNA represented by the nucleotide sequence of this gene or a complementary strand thereof, a homologue of the DNA, a protein encoded by the DNA, and a cell expressing the protein encoded by the DNA, an agent and a method for improving an anxiety condition, a method and an agent for prophylactic and/or therapeutic treatment of an anxiety disorder, and a measurement method for diagnosis and a diagnostic method of an anxiety disorder. | 2010-02-04 |
20100029703 | ANHYDROUS CRYSTALLINE VINFLUNINE SALTS, METHOD OF PREPARATION AND USE THEREOF AS A DRUG AND MEANS OF VINFLUNINE PURIFICATION - The present invention relates to anhydrous crystalline vinflunine salts obtained with 1 or 2 equivalents of a pharmaceutically acceptable mineral or organic acid [Acid] 1 or 2 in which [Acid] represents hydrobromic, sulfuric, lactic and fumaric acids for the group of water-soluble crystalline salts, and para-toluene sulfonic, benzoic, mandelic and para-hydroxy benzoic acids for the group of relatively insoluble crystalline salts. | 2010-02-04 |
20100029704 | SALT OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG AND ORGANIC AMINE COMPOUND AND USE THEREOF - The invention provides a salt, particularly an ionic liquid, of a non-steroidal anti-inflammatory drug (NSAID) comprising a carboxylic acid and an organic amine compound, as well as a method of producing such a salt. | 2010-02-04 |
20100029705 | BETA-2-ADRENORECEPTOR AGONISTS - Compounds of formula | 2010-02-04 |
20100029706 | HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS - Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, and diseases of aging such as diabetes and cancer with hydrogenated pyrido[4,3-b]indoles such as dimebolin, are disclosed. | 2010-02-04 |
20100029707 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF - The present invention provides a compound represented by the formula | 2010-02-04 |
20100029708 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER - Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions. | 2010-02-04 |
20100029709 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - A novel [1,2,4]triazolo[1,5-a]pyridine compound is disclosed that has a formula represented by the following: | 2010-02-04 |
20100029710 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES - Compounds of following formula (I) are provided that have both angiotensin II receptor antagonist activity and PPARy agonist activity. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment of diseases with the compounds including type 2 diabetes, insulin resistance, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, metabolic syndrome, congestive heart failure, and hypertension. | 2010-02-04 |
20100029711 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel chromen-2-one derivatives of Formula (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2010-02-04 |
20100029712 | Irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis - A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general surgical, therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents, including at least one local anesthetic agent, and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents. | 2010-02-04 |
20100029713 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula (I) wherein R | 2010-02-04 |
20100029714 | AQUEOUS PHARMACEUTICAL SUSPENSIONS CONTAINING REBAMIPIDE AND MANUFACTURING PROCESS THEREOF - The invention provides a rebamipide-containing aqueous pharmaceutical suspension which can be prepared by a simple process and keep the dispersed fine-particle state of rebamipide stable without having the fine particle agglutinated. The rebamipide-containing aqueous pharmaceutical suspension of the invention is prepared by mixing polyvinyl alcohol and additionally a sodium salt compound with rebamipide. | 2010-02-04 |
20100029715 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV - Provided are crystalline forms of the compound of formula (I), which is a macrocyclic inhibitor of HCV, processes for the preparation thereof, and pharmaceutical compositions comprising these crystalline forms. | 2010-02-04 |
20100029716 | NOVEL 1,2,3,4- TETRAHYDROQUINOLINE DERIVATIVES - The present invention relates to a novel derivative of Compound 1 selectively substituted with fluorine and/or deuterium and optionally further substituted with deuterium and | 2010-02-04 |
20100029717 | Alkylsulphonamide Quinolines - Compounds of Formula I | 2010-02-04 |
20100029718 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 2010-02-04 |
20100029719 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS - The present invention relates to sulfonamide derivatives of formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are useful in the treatment of neuronal disorders, autoimmune diseases, cancer and cardiovascular diseases. Furthermore, said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and -3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. | 2010-02-04 |
20100029720 | Carboxamide Derivatives As Muscarinic Receptor Antagonists - The invention relates to compounds of formula | 2010-02-04 |
20100029721 | Pharmaceutical Formulation Comprising Metformin and Repaglinide - The invention is related to a pharmaceutical composition comprising repaglinide in combination with metformin or a salt thereof in unit dosage form wherein a pre-formulation of the repaglinide has a pH independent dissolution profile and a relative humidity of less than about 25% prior to mixing with the metformin or a salt thereof; and optionally one or more pharmaceutically acceptable excipients and to a method for its preparation. | 2010-02-04 |
20100029722 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 2010-02-04 |
20100029723 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. | 2010-02-04 |
20100029724 | SCREENING METHOD - The present invention provides a method of screening for a therapeutic drug for diabetes or a nerve system disease, including using ferrochelatase, and a ferrochelatase activator containing a compound represented by the formula: | 2010-02-04 |
20100029725 | RESISTANCE MANAGEMENT STRATEGIES - Insect refuge strategies are described for the management of insect resistance development. The present invention relates generally to the control of pests that cause damage to crop plants, and in particular to corn plants, by their feeding activities directed to root damage, and more particularly to the control of such plant pests by exposing target pests to seeds or mixtures of seeds having multiple different modes of action. The first one or more transgenes and the second one or more transgenes are each, respectively, insecticidal to the same target insect but have different modes of action, and bind either semi-competitively or non-competitively to different binding sites in the target pest. In addition, the treatment of such seed with a chemical or peptide-associated pesticide prior to planting the seed is also disclosed. | 2010-02-04 |
20100029726 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA - The present invention provides compounds of formula I: | 2010-02-04 |
20100029727 | 1, 3, 4 -OXADIAZOLE DERIVATIVES AS DGAT1 INHIBITORS - Compounds of formula (I), or salts thereof, which inhibit acetyl CoA (acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, | 2010-02-04 |
20100029728 | PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of CNS diseases, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and their use as PDE type IV selective inhibitors, are provided. | 2010-02-04 |
20100029729 | COMPOUNDS - The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders. | 2010-02-04 |
20100029730 | THIAZOLYL BIPHENYL AMIDES - The invention relates to novel thiazolylbiphenylamides of the formula (I) | 2010-02-04 |
20100029731 | Method for preparing largazole analogs and uses thereof - Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described. | 2010-02-04 |
20100029732 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone - The invention provides a pharmaceutical product comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor)=Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azo-niabicyclo[2.2.2]octane bromide, 3(R)- | 2010-02-04 |
20100029733 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS - A nitrogen-containing bicyclic heterocyclic compound represented by the following formula (1) is provided. When the compound or a salt thereof is administered to a human being or an animal, the compound has a strong antagonistic action against EP1 receptors, and is useful, for example, as an active ingredient of a medicine for the prevention and/or treatment of overactive bladder. The compound is also useful as an active ingredient of a medicine for the prevention and/or treatment of symptoms such as frequency urinary, urinary urgency, or urinary incontinence. | 2010-02-04 |
20100029734 | METHODS FOR BREAST CANCER SCREENING AND TREATMENT - A method for selecting a breast cancer patient for therapy with an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, comprises (a) determining whether the cancer comprises a tumor that is estrogen receptor positive (ER+) and (b) selecting the patient for such therapy only if the cancer is determined to comprise an ER+ tumor. A method for treating breast cancer in a patient further comprises (c) administering to the patient, if so selected, an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor. A method for treating a breast tumor in a patient having SERM-resistant ER+ breast cancer comprises administering to the patient an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor. A therapeutic combination useful in treatment of a breast tumor comprises an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, and a second agent that comprises (a) an aromatase inhibitor or (b) an estrogen receptor modulator or antagonist. | 2010-02-04 |
20100029735 | THERAPEUTIC COMPOUNDS - Disclosed herein is a compound of the formula. Therapeutic methods, compositions, and medicaments for the treatment of glaucoma or ocular hypertension related thereto are also disclosed. | 2010-02-04 |
20100029736 | 2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to 2-substituted proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2010-02-04 |
20100029737 | INHIBITORS OF D-AMINO ACID OXIDASE - The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia. | 2010-02-04 |
20100029738 | Bicyclic Tetrahydropyrrole Compounds - The present invention relates to substituted bicyclic tetrahydropyrrole compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals. | 2010-02-04 |
20100029739 | Use of a combination of hypothermia inducing drugs - The present invention relates to the induction of hypothermia in humans in a predictable and dose responsive fashion by use of a pharmaceutical composition comprising a combination of (1) vanilloid receptor agonists, capsaicinoids or capsaicinoid-like agonists reaching and binding to vanilloid receptors, and (2) cannabinoids or cannabimimetic agonists reaching and binding to cannabinoid receptors, thereby inducing hypothermia, thus benefiting patients suffering from illnesses characterized by tissue anoxia. | 2010-02-04 |
20100029740 | AZABICYCLIC COMPOUNDS AS SEROTONIN, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE INHIBITORS - Novel compounds of formula (I)′ and pharmaceutically acceptable salts, solvates and prodrugs thereof: | 2010-02-04 |
20100029741 | FUSED HETEROCYCLES - This invention provides methods of improving cognitive function by administering to a subject a therapeutically effective amount of a fused heterocycle having the formula: | 2010-02-04 |
20100029742 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN - The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F), the crystal modification 2 (polymorphic form I), and the crystal modification 3 (polymorphic form X) of the mono-sodium salt of D-isoglutamyl-D-tryptophan. | 2010-02-04 |
20100029743 | ATORVASTATIN PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical formulations of atorvastatin or its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs or their mixtures; and processes for preparing the same, and their methods of use, treatment and administration. Further, the present invention relates to pharmaceutical compositions comprising an acid-solubility-enhanced form of atorvastatin or its salts. | 2010-02-04 |
20100029744 | Methods for Alzheimer's Disease Treatment and Cognitive Enhancement - The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate α-secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition. | 2010-02-04 |
20100029745 | DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE - The present invention relates to compounds derived from substituted 3-phenyl-1-(thien-2-yl)propan-1-ones, pharmaceutical compositions comprising them as well as their therapeutic applications, notably in the field of human and animal health. | 2010-02-04 |
20100029746 | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes - The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating or preventing the incidence or severity of hearing impairment (or balance impairment), particularly hearing impairment associated with cell death of the inner ear hair cells or outer ear hair cells, comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. | 2010-02-04 |
20100029747 | METHODS AND COMPOSITIONS FOR INHIBITING THE FUNCTION OF POLYNUCLEOTIDE SEQUENCES - A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell. In methods of treatment of prophylaxis of virus infections, other pathogenic infections or certain cancers, these compositions are administered in amounts effective to reduce or inhibit the function of the target polynucleotide sequence, which can be of pathogenic origin or produced in response to a tumor or other cancer, among other sources. | 2010-02-04 |
20100029748 | Metastasis Promoting Genes and Proteins - Two sets of genes and their encoded proteins, one set of 17 genes/proteins and one set of 18 genes/proteins that can be used in predicting the risk of cancer metastasis to the brain, and as a screening assay to identify the suitable treatments for brain metastases. Genes/proteins within the sets that are found to be differentially expressed relative to a control value are suitable targets for therapy. | 2010-02-04 |
20100029749 | Chimeric NK Receptor and Methods for Treating Cancer - The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided. | 2010-02-04 |
20100029750 | NOVEL CROSSLINKED PEI NANOPARTICLE BASED TRANSFECTION AGENTS FOR DELIVERY OF BIOMOLECULES - The present invention relates to a novel crosslinked polyethylenimine (PEI) nanoparticle based nucleic acid transfection agent wherein the crosslinker is having carbon chain in the range of C2 to C8, ranging between 3.27-19.8%, having the size of nanoparticle ranging between 20-600 nm and zeta potential ranging from +5 to 50 mV. | 2010-02-04 |
20100029751 | COMPOSITIONS COMPRISING A PARVOVIRUS VP1-VARIANT AND A PARVOVIRUS NS1 PROTEIN FOR INDUCTION OF CYTOLYSIS - The present invention provides a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention provides DNA sequences encoding said proteins. The composition of the invention is useful for the preparation of a toxin for treating tumoral diseases. | 2010-02-04 |
20100029752 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME - A pharmaceutical composition containing a pharmaceutical diluent and a compound of formula II: wherein: R | 2010-02-04 |
20100029753 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF - Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity. | 2010-02-04 |
20100029754 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 - The invention relates to thiophene carboxamides of formula (I), | 2010-02-04 |
20100029755 | P-Glycoprotein inhibitor comprising octilonium bromide as an effective ingredient - The present invention relates to a new use of octylonium bromide as p-glycoprotein inhibitor to increase cellular uptake of drugs. More particularly, the present invention provides octylonium bromide as a p-glycoprotein inhibitor to increase cellular uptake of drugs such as anticancer drugs by taking octylonium bromide simultaneously with or proceeding drug administration. | 2010-02-04 |
20100029756 | NOVEL COMPOSITIONS CONTAINING ISOLATED TETRAMERIC TYPE A PROANTHOCYANADIN AND METHODS OF USE AND MANUFACTURE - The present invention relates to compositions containing an isolated novel tetrameric type A proanthocyanidin isomer having a formula of C | 2010-02-04 |
20100029757 | USE OF XANTHOHUMOL AND/OR ISOXANTHOHUMOL AS AN AGENT FOR PREVENTING AND/OR COMBATING LIVER DISEASES - The present invention relates to the use of xanthohumol with formula (I) as an agent for the production of a preparations for preventing and/or combating liver diseases. | 2010-02-04 |
20100029758 | DERIVATIVES OF ISOFLAVONES - The present invention discloses novel isoflavone conjugates and their use for affinity targeting of drugs, imaging and detection agents to cells having estrogen receptors, particularly estrogen receptors subtype β. | 2010-02-04 |
20100029759 | COMPOSITION USEFUL FOR THE TREATMENT OF TYPE 2 DIABETES - It is described the use of L-canitine and/or an alkanoyl L-canitine, or a pharmaceutically acceptable salt thereof, in combination with a statin, for the preparation of a medicament for the treatment of type 2 diabetes. | 2010-02-04 |
20100029760 | Obesity and Metabolic Syndrome Treatment with Tanshinone Derivatives Which Increase Metabolic Activity - The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient. | 2010-02-04 |
20100029761 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME - A pharmaceutical diluent and a compound of formula VI: wherein: R10=H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms; R11=H3 or C]-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms; R12=H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms, —C(O)R13, where R13 is H, Ci-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms, or —OH, —OR14 or —NR14, where R14 is H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms. | 2010-02-04 |
20100029762 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris - A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor. | 2010-02-04 |
20100029763 | METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES - The present invention refers to new derivatives of the penta-1,4-dien-3-ones, as well as their processes of preparation. These compounds present strong antitumoral activity and promising antiparasitic action, behaving as almost atoxic by laboratory assays and also by hystopathologic studies. The present invention refers also to a pharmaceutical composition including the referred compounds, method of treatment for cancer and parasitic diseases. | 2010-02-04 |
20100029764 | COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE-MEDIATED INTRACELLULAR SIGNAL TRANSDUCTION - Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and/or conformational changes in membranous structures (e.g., membrane proteins, receptors and/or other components) including G-protein coupled receptors (GPCRs), G-proteins, and/or intracellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). | 2010-02-04 |
20100029765 | TOPICAL AQUEOUS COMPOSITION COMPRISING TRETINOIN - Topical aqueous compositions for the treatment of a skin disorder particularly acne. Topical aqueous composition comprising tretinoin and a hydrophilic cellulose derivative as a gelling agent, wherein the composition has a pH of about 4 to about 6.5 and viscosity of less than about 20,000 cP or provided. The composition also relates to the topical administration of tretinoin in combination with an antibiotic. | 2010-02-04 |
20100029766 | Blends Comprising a Substituted Fatty Acid or a Derivative Thereof - The invention concerns blends of a hydroquinone substituted poly unsaturated fatty acid (as present in Kombo nut oil) or a derivative thereof, which blends comprised:
| 2010-02-04 |
20100029767 | ANTHRANILIC ACID DERIVATIVES - Compounds of formula (I) are provided, wherein X is CH═CH, CH | 2010-02-04 |
20100029768 | Compositions and Methods For Promoting Fat Loss - This invention provides diets useful for promoting fat loss in animals having a total lysine to metabolizable energy ratio of from about 6 to about 10 g/Mcal. This invention also provides compositions for promoting fat loss in animals, methods for preparing the compositions, methods for using the diets and compositions, articles of manufacture comprising the diets and compositions, and means for communicating information or instructions about such diets, compositions, methods, and articles of manufacture. | 2010-02-04 |
20100029769 | TOPICAL FORMULATION - There is described a topical formulation. The topical formulation comprises: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. | 2010-02-04 |
20100029770 | Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism - Subjects having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism are treated with a composition that includes gamma-aminobutyric acid agonists and/or M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and M1 muscarinic receptor antagonists in methods of treating humans. | 2010-02-04 |
20100029772 | Dicarboxylic Acid Derivatives and their Use - The present application relates to novel dicarboxylic acid derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders. | 2010-02-04 |
20100029773 | Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift) - The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit. | 2010-02-04 |
20100029774 | ALISKIREN MONOFUMARATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides a novel fumarate compound of aliskiren monofumarate, and process for preparation thereof. The present invention also provides pharmaceutical compositions comprising aliskiren monofumarate, and methods of using aliskiren monofumarate for treating hypertension. | 2010-02-04 |
20100029775 | RENIN INHIBITORS FOR THE PREVENTION AND TREATMENT OF HYPERTENSION IN OBESE PATIENTS - The present invention relates to methods for the prevention of, delay progression to or treatment of hypertension in obese patients, comprising administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof. | 2010-02-04 |
20100029776 | PESTICIDAL COMPOSITION COMPRISING FENAMIDONE AND AN INSECTICIDE COMPOUND - A composition comprising fenamidone (a) and an insecticide compound (b) in a (a)/(b) weight ratio of from 1/1000 to 1000/1. | 2010-02-04 |
20100029777 | 4-[(E)-2-(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPTHALENYL)-1-PROPENYL- ]BENZOIC ACID ANALOGS AND METHOD OF MANUFACTURE AND USE THEREOF - Analogs of 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid and methods of manufacture and use thereof, such as for use in cancer prevention and treatment. | 2010-02-04 |
20100029778 | HAIR AND/OR SCALP TREATMENT COMPOSITIONS - Hair and/or scalp treatment compositions comprise an antidandruff agent, an effective amount of a cannabinoid receptor (CBR) activating agent and a cosmetically acceptable diluent or carrier. Alternatively, the compositions may be shampoo compositions comprising from 3 to 50 wt % surfactant, a CB receptor activating agent and a cosmetically acceptable diluent or carrier, provided that the CB receptor activating agent is not palmitoylethanolamide. The compositions are useful in the treatment and/or prevention of the symptoms of dandruff and can reduce scalp itch, a symptom which is typically associated with dandruff. | 2010-02-04 |
20100029779 | COMPOSITION AND METHOD FOR TREATMENT OF MRSA - The present invention provides a photosensitizing composition for treatment of MRSA comprising a photosensitizer and chlorhexidine and a pharmaceutically acceptable carrier. The present invention also provides a method for reducing disease causing microbes comprising: applying the composition comprising a photosensitizer, chlorhexidine at a concentration of more than about 0.01% and less than about 2% v/v, and a pharmaceutically acceptable carrier to a treatment site; and applying light to the treatment site at a wavelength absorbed by the photosensitizer so as to reduce the microbes at the treatment site. | 2010-02-04 |
20100029780 | TOPICAL COMPOSITION - A topical composition comprising at least one C | 2010-02-04 |
20100029781 | METHODS FOR PREPARATION OF ANTI-ACNE FORMULATION AND COMPOSITIONS PREPARED THEREBY - The present invention provides methods to make solvent-microparticle (SMP) topical formulations for bioactive drugs. The formulations, which are aqueous gels containing undissolved solid drug, include a drug in a solution which can permeate the stratum corneum layer of the epidermis and the drug in an undissolved microparticulate solid form that does not readily cross the stratum corneum. The solid form is retained in or above the stratum corneum to serve as a reservoir or to provide drug action in the supracorneum zone. The fine, particulate solid component of the invention can confer a smooth, nongritty feel against the skin. | 2010-02-04 |
20100029782 | Calcilytic Compounds - Novel calcilytic compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods of using them are provided. | 2010-02-04 |
20100029783 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME - A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of the alkylating agent to the affected skin, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol. | 2010-02-04 |
20100029784 | NAPHTHOQUINONE COMPOSITIONS WITH ANTI-AGING, ANTI-INFLAMMATORY AND SKIN EVEN-TONING PROPERTIES - The present invention relates to methods and compositions comprising naphthoquinones such as 2,3-dimethylnaphthalene-1,4-dione, for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible and/or tactile discontinuities of the skin resulting from skin pigmentation or skin aging are also disclosed. | 2010-02-04 |
20100029785 | PARTICLE COMPOSITIONS WITH A PRE-SELECTED CELL INTERNALIZATION MODE - A method of formulating a particle composition having a pre-selected cell internalization mode involves selecting a target cell having surface receptors and obtaining particles that have i) surface moieties, that have an affinity for or are capable of binding to the surface receptors of the cell and ii) a preselected shape, where a surface distribution of the surface moieties on the particles and the shape of the particles are effective for the pre-selected cell internalization mode. | 2010-02-04 |
20100029786 | Flavor improving agent, and food and drink containing the same - The present invention provides a novel flavor improving agent capable of sufficiently enhancing or alleviating the flavor sensed in oral cavity; for example, enhancing and improving the thickness in taste or the like to provide depth and profoundness to the flavor, and also improving the sense of volume or the sharpness of aftertaste. The present invention also provides a food/drink, a pharmaceutical product and an oral care product having a good taste which can fulfill the recent high-level demand for taste. | 2010-02-04 |
20100029787 | Thickener, Cosmetic Preparation Containing The Same, And Process For Producing The Same - The present invention is a thickener consisting of a microgel obtained by radical polymerization of water soluble ethylene-type unsaturated monomers dissolved in the dispersion phase in a composition having an organic solvent or an oil component as the dispersion medium and water as the dispersion phase, as well as a cosmetic containing said thickener. | 2010-02-04 |
20100029788 | WET EDIBLE PEARLESCENT FILM COATINGS - Provided herein are wet powder compositions which include a pearlescent pigment, a film-forming edible polymer and from about 1% to about 30% by weight water. The wet powder compositions may be used to make pearlescent film coating suspensions which include a pearlescent pigment, a film-forming polymer, a plasticizer and from about 70% to about 95% water. The pearlescent film coating suspensions may be used to coat edible products, such as pharmaceuticals, confectionary products and food products. Also disclosed are methods of making the wet powder compositions and the pearlescent film coating suspensions. | 2010-02-04 |
20100029789 | Load Bearing Hydrogel Implants - The present invention features dual network hydrogels that possess the structural, mechanical, and biological properties required of load bearing three-dimensional support structures. | 2010-02-04 |
20100029790 | SOLID FILM, RAPIDLY DISSOLVABLE IN LIQUIDS - A solid film rapidly dissolvable in liquids, in particular biological liquids, to release pharmaceutical, cosmetic and nutrient substances. The solid film is also soluble in biological organic liquids to protect wounds of the human body by releasing cicatrizing, disinfectant and cosmetic substances. The film can also be used to release flavouring substances directly onto moist nutrient products. | 2010-02-04 |
20100029791 | METHOD FOR PRODUCING VESICLE, VESICLE OBTAINED BY THE PRODUCTION METHOD, AND METHOD FOR PRODUCING FROZEN PARTICLE USED IN PRODUCTION OF VESICLE - A W/O emulsion is produced from an aqueous solution containing a substance to be entrapped in a vesicle in a dissolved or suspended state and an oil phase containing an emulsifier; subsequently, the W/O emulsion is cooled to a temperature at which the aqueous solution of the W/O emulsion becomes a frozen particle and the oil phase maintains a liquid state, and the oil phase is removed; thereafter, an oil phase containing a vesicle constituent lipid is added to the frozen particle, and the obtained mixture is then stirred, so as to substitute the emulsifier on the surface of the frozen particle with the vesicle constituent lipid; and thereafter, an external water phase is added to the frozen particle coated with a lipid membrane, so as to hydrate the lipid membrane by the external water phase. This process achieves a high entrapment yield of a desired substance while controlling desired physical properties such as particle diameter. | 2010-02-04 |
20100029792 | COBALT-BASED CATLAYST FOR FISCHER-TROPSCH SYNTHESIS - The invention relates to a catalyst which can be applied to a method for converting synthesis gas, said catalyst comprising: a) a support made of a solid solution containing at least one first aluminate element with a mixed spinel structure of formula M | 2010-02-04 |
20100029793 | METHODS OF MANUFACTURE OF POLYLACTIC ACID FOAMS - A method of forming a composition of expanded polylactic acid (PLA) resin beads comprising impregnating PLA resin beads with CO | 2010-02-04 |
20100029794 | Methods for Making Polymer Beads - The present invention relates to a polymer bead material that are characterised by having pore sizes that can be pre-determined and that can be obtained with a narrow distribution of such pore sizes created by use of sacrificial filler materials within the polymer material. The invention also discloses processes for production of the material as spherical or approximately spherical beads or resins with predefined sizes. Also, the invention relates to the preparation of molecularly imprinted polymer materials that are created by the said method. Further the invention relates to the use of said polymer materials for separation, detection, catalysis or entrapment of chemicals, metal ions, inorganic compounds, drags, peptides, proteins, DNA, natural and artificial polymers, natural or artificial compounds, food or pharma products, viruses, bacteria, cells and other entities. | 2010-02-04 |
20100029795 | Porous carbons - A method is provided for making mesoporous resin. It comprises:
| 2010-02-04 |
20100029796 | PROCESS FOR THE PREPARATION OF AUXETIC FOAMS - A process for the preparation of thermoplastic auxetic foams comprising the steps of: a) taking conventional thermoplastic foam; b) subjecting said foam to at least one process cycle wherein the foam is biaxially compressed and heated; c) optionally subjecting the foam to at least one process cycle wherein the biaxial compression is removed and the foam mechanically agitated prior to reapplying biaxial compression and heating; d) cooling said foam to a temperature below the softening temperature of said foam; and e) removing said compression and heat. | 2010-02-04 |
20100029797 | BIOCIDAL PARTICLES OF METHYLATED POLYSTYRENE - Methylated polystyrene having pendant N-halamine and N-halamine precursor groups. Biocidal particles have been prepared by reacting highly crosslinked methylated polystyrene beads as starting materials with various N-halamine precursor compounds. The resulting polymer beads are halogenated with chlorine or bromine. The porous beads will be useful in disinfection applications as well as for sanitization and controlling noxious odor when mixed with absorbent materials in items such as disposable diapers, infant swimwear, incontinence pads, bandages, sanitary napkins, pantiliners, mattress covers, shoe inserts, sponges, animal litter, carpets, and fabrics. | 2010-02-04 |
20100029798 | Polyurethane Elastic Memory Material that Emits Nano-negative Ion Far Infrared Rays and a Method for Preparing the Same - A polyurethane elastic memory material that emits nano-negative ion far infrared rays and a method for preparing the same is disclosed. A nano-negative ion far infrared ray emitting additive that belongs to the Lianfuya Established Series is added to polyester and/or polyether polyol to create a polyurethane elastic memory foam material that emits negative ions at a rate of 3,000 negative ions/cm | 2010-02-04 |